187 related articles for article (PubMed ID: 16684078)
1. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone.
Elder G; Faull R; Branley P; Hawley C;
Nephrology (Carlton); 2006 Apr; 11 Suppl 1():S230-61. PubMed ID: 16684078
[No Abstract] [Full Text] [Related]
2. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
Yaginuma T; Yamamoto H
Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
[TBL] [Abstract][Full Text] [Related]
3. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
Akiba T
Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. How many measurements to make a decision?
Houillier P; Coste J; Froissart M
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1161-2. PubMed ID: 20558565
[No Abstract] [Full Text] [Related]
6. The CARI guidelines. Biochemical targets.
Hawley C; Elder G;
Nephrology (Carlton); 2006 Apr; 11 Suppl 1():S198-216. PubMed ID: 16684076
[No Abstract] [Full Text] [Related]
7. Effects of dialysis prescription on bone and mineral metabolism: the National Cooperative Dialysis Study.
Harter HR; Laird NM; Teehan BP
Kidney Int Suppl; 1983 Apr; (13):S73-9. PubMed ID: 6345900
[No Abstract] [Full Text] [Related]
8. [Systemic diseases affecting the skeletal system].
Hehrmann R; Eliwo-Bamokyaka M
Z Gastroenterol Verh; 1986 Apr; 21():27-34. PubMed ID: 2422837
[No Abstract] [Full Text] [Related]
9. Treatment of hyperparathyroidism--why is it crucial to control serum phosphate?
Brancaccio D; Gallieni M; Cozzolino M
Nephrol Dial Transplant; 1996 Mar; 11(3):420-3. PubMed ID: 8671808
[No Abstract] [Full Text] [Related]
10. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?
Gal-Moscovici A; Sprague SM; Hutchison AJ; Shah N; Piraino B; Cunningham J
Semin Dial; 2007; 20(1):24-32. PubMed ID: 17244115
[No Abstract] [Full Text] [Related]
11. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
[No Abstract] [Full Text] [Related]
12. Vitamin D deficiency and associated factors in hemodialysis patients.
Jean G; Charra B; Chazot C
J Ren Nutr; 2008 Sep; 18(5):395-9. PubMed ID: 18721733
[TBL] [Abstract][Full Text] [Related]
13. National haemodialysis guidelines: an assessment of compliance from 2001-2003.
Bannister KM; Snelling P;
Nephrology (Carlton); 2006 Apr; 11(2):90-6. PubMed ID: 16669967
[TBL] [Abstract][Full Text] [Related]
14. [Vitamin D and bone disease due to dialysis].
Kurokawa K
Nihon Naika Gakkai Zasshi; 1992 Sep; 81(9):1397-400. PubMed ID: 1333507
[No Abstract] [Full Text] [Related]
15. Calcium and the endocrine system.
O'Riordan LH
Practitioner; 1982 Feb; 226(1364):237-41. PubMed ID: 6896382
[No Abstract] [Full Text] [Related]
16. Renal osteodystrophy and its treatment.
Duursma SA; Mees EJ
Neth J Med; 1973; 16(2):101-7. PubMed ID: 4705764
[No Abstract] [Full Text] [Related]
17. Residual renal function plays an important role in regulating parathyroid hormone in patients on continuous ambulatory peritoneal dialysis.
Okada S; Inoue T; Nakamoto H; Ikeda N; Sugahara S; Shoda J; Okada H; Kanno Y; Suzuki H
Adv Perit Dial; 2007; 23():150-4. PubMed ID: 17886623
[TBL] [Abstract][Full Text] [Related]
18. Low-calcium dialysate worsens secondary hyperparathyroidism.
Argilés A; Mion CM
J Am Soc Nephrol; 1996 Apr; 7(4):635-6. PubMed ID: 8724901
[No Abstract] [Full Text] [Related]
19. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
20. Limitation by hyperphosphataemia of the "prophylactic" use of vitamin D metabolites in the treatment of osteitis fibrosa in patients on chronic haemodialysis.
de Fremont JF; Sebert JL; Gueris J; Marie P; Coevoet B; Makdassi R; Lambrey G; Meunier P; Fournier A
Proc Eur Dial Transplant Assoc; 1979; 16():675-6. PubMed ID: 232918
[No Abstract] [Full Text] [Related]
[Next] [New Search]
